Denali Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.588; its P/E ratio is -8.85; Denali Therapeutics is scheduled to report earnings on November 2, 2023, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	$ 10.28M	$ 3.56M	$ 52.48M	$ 42.14M	$ 12.51M
Gross Profit	-	-	-	-	-
EBIT	$ -105.34M	$ -107.49M	$ -61.42M	$ -66.50M	$ -77.12M
EBITDA	$ -101.25M	$ -105.34M	$ -59.34M	$ -64.42M	$ -75.03M
Net Income Common Stockholders	$ -98.68M	$ -103.30M	$ -58.79M	$ -65.22M	$ -75.26M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 1.34B	$ 1.11B	$ 1.07B	$ 957.52M	$ 865.41M
Total Assets	$ 1.46B	$ 1.23B	$ 1.29B	$ 1.32B	$ 1.40B
Total Debt	$ 60.35M	$ 62.05M	$ 61.40M	$ 62.74M	$ 64.01M
Net Debt	$ -1.28B	$ -1.04B	$ -1.01B	$ -894.78M	$ -801.40M
Total Liabilities	$ 417.81M	$ 416.30M	$ 408.01M	$ 402.93M	$ 441.87M
Stockholders Equity	$ 1.04B	$ 811.30M	$ 884.45M	$ 917.93M	$ 962.29M
Cash Flow	-
Free Cash Flow	$ -77.51M	$ -63.10M	$ -45.79M	$ -76.15M	$ -68.55M
Operating Cash Flow	$ -72.66M	$ -57.05M	$ -42.90M	$ -72.11M	$ -65.49M
Investing Cash Flow	$ -127.56M	$ 15.42M	$ 88.63M	$ -117.88M	$ -40.75M
Financing Cash Flow	$ 299.65M	$ 5.15M	$ 4.40M	$ 1.46M	$ 5.17M

Currency in USD

Denali Therapeutics Earnings and Revenue History

Income Statement >

Denali Therapeutics Debt to Assets

Balance Sheet >

Denali Therapeutics Cash Flow

Cash Flow >

Denali Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing